Mosaic ImmunoEngineering (CPMV) Return on Capital Employed (2011 - 2026)
Mosaic ImmunoEngineering (CPMV) posted quarterly Return on Capital Employed of 9.67% for Q1 2026, down 452.0% year-over-year from 2.75% in Q1 2025, and down 5.91% quarter-over-quarter from 10.28% in Q4 2025.
Mosaic ImmunoEngineering (CPMV) Return on Capital Employed (2011 - 2026) Analysis & Trends
Mosaic ImmunoEngineering's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 9.67% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 452.0% year-over-year to 9.67%; the TTM figure through Mar 2026 stood at 9.67% (down 452.0% YoY), while the FY2025 annual figure was 10.36%, down 600.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 9.67%, down from 10.28% in the prior quarter.
- The five-year high for Return on Capital Employed was 146.9% in Q1 2022, with the low at 9.67% in Q1 2026.
- The 5-year median for Return on Capital Employed is 25.36% (2024), against an average of 43.32%.
- The sharpest annual moves came in 2022 and 2026: Return on Capital Employed sank 14834 bps in 2022, then tumbled 452 bps in 2026.
- Mosaic ImmunoEngineering's Return on Capital Employed stood at 73.59% in 2022, then plunged by 58 bps to 31.1% in 2023, then tumbled by 48 bps to 16.15% in 2024, then tumbled by 36 bps to 10.28% in 2025, then fell by 6 bps to 9.67% in 2026.
- Business Quant data shows CPMV's Return on Capital Employed at 9.67% in Q1 2026, 10.28% in Q4 2025, and 10.55% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 7.88% |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - | 9.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.67% |
| Dec 31, 2025 | 10.28% |
| Sep 30, 2025 | 10.55% |
| Jun 30, 2025 | 11.60% |
| Mar 31, 2025 | 14.19% |
| Dec 31, 2024 | 16.15% |
| Sep 30, 2024 | 19.05% |
| Jun 30, 2024 | 22.35% |
| Mar 31, 2024 | 25.36% |
| Dec 31, 2023 | 31.10% |
| Sep 30, 2023 | 38.23% |
| Jun 30, 2023 | 44.70% |
| Mar 31, 2023 | 59.45% |
| Dec 31, 2022 | 73.59% |
| Sep 30, 2022 | 90.37% |
| Jun 30, 2022 | 112.96% |
| Mar 31, 2022 | 146.90% |
| Dec 31, 2021 | 180.68% |
| Sep 30, 2021 | 238.71% |
| Jun 30, 2021 | 239.00% |